1. Home
  2. CRVO

CRVO

CervoMed Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.

Founded: 2001 Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 155.5M IPO Year: N/A
Target Price: $65.00 AVG Volume (30 days): 29.7K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.82 EPS Growth: N/A
52 Week Low/High: $3.00 - $26.38 Next Earning Date: 05-13-2024
Revenue: $7,144,872 Revenue Growth: N/A
Revenue Growth (this year): 25.63% Revenue Growth (next year): -19.32%

Share on Social Networks: